Want to see FR:MAAT full AI Analyst Report?

MaaT Pharma (MAAT) Price & Analysis

5 Followers

MAAT Stock Chart & Stats

€5.51

€1.22(15.21%)

At close: Jan 09 4:00 PM EST

€5.51

€1.22(15.21%)

Day’s Range― - ―

52-Week Range€2.32 - €8.62

Previous CloseN/A

Volume44.42K

Average Volume (3M)99.82K

Market Cap

€49.78M

Enterprise Value€38.21M

Total Cash (Recent Filing)€24.87M

Total Debt (Recent Filing)€17.44M

Price to Earnings (P/E)―

Beta-0.05

Next Earnings

Sep 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.95

Shares Outstanding18,856,394

10 Day Avg. Volume94,708

30 Day Avg. Volume99,816

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)42.60

Price to Sales (P/S)16.94

P/FCF Ratio-4.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.81

Revenue Forecast (FY)€8.96M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRobust positive Phase 3 data support MaaT013 efficacy and safety, and de-risk a planned follow-on Phase 3 study in the U.S.

Product PotentialALSFRS-R slopes numerically improved post-treatment, suggesting a potential benefit.

Regulatory ApprovalA Marketing Authorization Application submission to the EMA for MaaT013 approval in Europe is anticipated as a positive catalyst.

Bears Say

Financial HealthThe pressing issue is to secure additional funding, as the company's cash position only extends to the second quarter of 2025.

Market ChallengesRisks to the investment thesis include failure of clinical trials, regulatory requirements for additional studies, and the potential need to raise additional funds under poor market conditions.

MaaT Pharma News

MaaT Pharma: EMA Review, Robust Pipeline, and Solid Cash Runway Underpin Buy Rating and Upside Potential

In a report released today, Clémence Thiers from Stifel Nicolaus maintained a Buy rating on MaaT Pharma, with...

3M ago

Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus

Clémence Thiers, an analyst from Stifel Nicolaus, maintained the Buy rating on MaaT Pharma (MAAT – Research Report)....

1y ago

Buy Rating for MaaT Pharma Driven by Promising Clinical Developments and Strategic Financial Projections

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on MaaT Pharma (MAAT – Research Report) today and...

1y ago

Buy Rating for MaaT Pharma: Promising Phase 3 Results and Strategic Growth Catalysts

Vernon Bernardino, an analyst from H.C. Wainwright, has initiated a new Buy rating on MaaT Pharma (MAAT). Vernon...

1y ago

MaaT Pharma’s Strong Financial Position and Promising Clinical Developments Drive Buy Rating

In a report released today, Clémence Thiers from Stifel Nicolaus maintained a Buy rating on MaaT Pharma (MAAT...

1y ago

MaaT Pharma’s Promising Outlook: Buy Rating Backed by Positive DSMB Review and Strong Phase 3 Results for MaaT013

Analyst Clémence Thiers of Stifel Nicolaus maintained a Buy rating on MaaT Pharma (MAAT – Research Report), retaining...

1y ago

MAAT FAQ

What was MaaT Pharma’s price range in the past 12 months?

MaaT Pharma lowest stock price was €2.32 and its highest was €8.62 in the past 12 months.

What is MaaT Pharma’s market cap?

MaaT Pharma’s market cap is €49.78M.

When is MaaT Pharma’s upcoming earnings report date?

MaaT Pharma’s upcoming earnings report date is Sep 29, 2026 which is in 87 days.

How were MaaT Pharma’s earnings last quarter?

MaaT Pharma released its earnings results on Mar 31, 2026. The company reported -€0.951 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.951.

Is MaaT Pharma overvalued?

According to Wall Street analysts MaaT Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MaaT Pharma pay dividends?

MaaT Pharma does not currently pay dividends.

What is MaaT Pharma’s EPS estimate?

MaaT Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MaaT Pharma have?

MaaT Pharma has 18,856,394 shares outstanding.

What happened to MaaT Pharma’s price movement after its last earnings report?

MaaT Pharma reported an EPS of -€0.951 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.492%.

Which hedge fund is a major shareholder of MaaT Pharma?

Currently, no hedge funds are holding shares in FR:MAAT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

MaaT Pharma

MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.